短病程Graves病患者接受放射性碘消融时口服或静脉类固醇预防眼眶病的前瞻性随机对照研究
本研究将99例GDd<5年且无GO或仅有非活动性GO的甲亢患者随机分为静脉GC组(N=49)和口服GC组(N=50),在RAI前给予类固醇预防;另22例GDd>5年患者不接受类固醇作为对照。结果显示预防组无GO发生,对照组1例出现暂时性GO再激活;RAI后TRAb显著升高,但45天时接受类固醇者升高幅度小于未预防者。结论认为GDd<5年患者可通过类固醇预防RAI诱发的GO,GDd>5年患者可能无需此类治疗。
要点
- GDd<5年患者RAI前给予口服或静脉类固醇预防,随访期间无GO发生。
- 未预防的GDd>5年对照组中1例出现暂时性GO再激活,恢复甲功正常后自行好转。
- RAI后TRAb显著升高(p<0.0001),但45天时类固醇组升高幅度小于未预防组(p<0.01)。
核心结论
- GDd<5年患者通过类固醇可预防RAI诱发的GO。
- GDd>5年患者可能无需此类治疗。
- RAI后TRAb升高的减弱可能与类固醇的预防作用有关。
研究设计与样本
- 前瞻性随机对照研究,99例GDd<5年无GO或仅有非活动性GO的甲亢患者随机接受静脉GC(N=49)或口服GC(N=50)预防,22例GDd>5年患者未接受类固醇作为对照。
- 所有患者在RAI前及RAI后45、90、180天和5年随访期间接受眼科评估,并检测血清TRAb、甲状腺激素和甲状腺体积。
主要发现
- 预防组无患者在RAI后发生GO。
- 对照组1例女性未接受类固醇预防,TSH显著升高,出现暂时性GO再激活,恢复甲功正常后自行好转。
- RAI后12和20个月随访时,2例患者发生显性视神经病变。
- 甲状腺体积较小与RAI诱发甲减的患病率较高相关。
- RAI后血清TRAb显著升高(p<0.0001),但45天时接受类固醇者升高幅度小于未预防者(p<0.01)。
临床怎么用
- 作者认为,GDd<5年患者RAI前给予类固醇可预防RAI诱发的GO。
- 作者认为,GDd>5年患者可能无需类固醇预防。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Radioiodine (RAI) is a known risk factor for activation or de novo occurrence of Graves' orbitopathy (GO). Several studies demonstrated that GO can be prevented by glucocorticoids (GCs) in patients with pre-existing GO. We have previously shown that Graves' disease duration (GDd) <5 years is a risk factor for RAI-induced GO. We studied the effect of prophylaxis with either oral GCs (OGCs) or intravenous GCs (IVGCs) on GO activation in patients with GDd. Methods: In total, 99 hyperthyroid patients without GO or with pre-existing inactive GO with GDd <5 years were randomized to receive IVGCs (N = 49) or OGCs (N = 50) before RAI; 22 patients with GDd >5 did not receive steroids and were studied as controls. All patients underwent ophthalmological assessment before and 45, 90, 180 days and for a 5-year follow-up after RAI. Serum thyrotropin (TSH) receptor antibodies (TRAbs), thyroid hormones, and thyroid volume (TV) were also measured in response to RAI therapy and steroid prophylaxis. Results: No patient on prophylaxis developed GO after RAI. One woman of the control group, without steroid prophylaxis, and who had a marked elevation of her TSH, showed transient reactivation of GO, which spontaneously improved after restoring euthyroidism. On follow-up at 12 and 20 months after RAI, two patients developed overt optic neuropathy. A smaller TV was associated with a higher prevalence of RAI-induced hypothyroidism. Serum TRAbs increased significantly after RAI (p < 0.0001) but less in patients receiving steroids than in those without prophylaxis at 45 days (p < 0.01). Conclusions: The risk of RAI-induced GO can be prevented in all patients with GDd <5 years by steroids. Such treatment may not be necessary in patients with GDd >5 years. The blunting of TRAb elevation after RAI may be related to the prophylactic effect of steroids.
引用
- Vannucchi G, Covelli D, Campi I, et al. Prevention of Orbitopathy by Oral or Intravenous Steroid Prophylaxis in Short Duration Graves' Disease Patients Undergoing Radioiodine Ablation: A Prospective Randomized Control Trial Study. Thyroid. 2019. PMID: 31860407. doi:10.1089/thy.2019.0150
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。